Literature DB >> 3967174

Long-term results and prognostic factors in patients with differentiated thyroid carcinoma.

M Tubiana, M Schlumberger, P Rougier, A Laplanche, E Benhamou, P Gardet, B Caillou, J P Travagli, C Parmentier.   

Abstract

A multivariate analysis of the prognostic factors was carried out on a series of 546 differentiated thyroid cancers followed for 8 to 40 years. For survival, the highest risk factor was associated with age; tumors diagnosed in patients younger than 45 years had higher relapse-free survival (RFS) and total survival (TS) rates and a slower growth rate. In children, although the RFS and TS at 15 years were high, they decreased later. The second independent prognostic factor was histology. There was no difference between papillary and follicular well-differentiated (FWD) tumors, but follicular moderately differentiated (FMD) had lower TS and RFS. Among FMD cancers, relapses occurred earlier and the interval between relapse and death was shorter. The third factor was sex. Tumors tended to disseminate more in male than in female patients. The survival rate after relapse was the same, however, suggesting that the growth rates are not different. The presence of palpable lymph nodes also had a significant independent impact on both TS and RFS. Patients treated after 1960 have a better outcome than patients treated earlier, although they did not differ in age distribution, histologic characteristics, sex ratio, or incidence of palpable lymph nodes. The distribution of time intervals between treatment and relapse was not compatible with an exponential failure time model but fit with a log-logistic model. Relapses can occur as late as 30 years or more after initial treatment. Elevated levels of circulating thyroglobulin have been observed in about 12% of the patients who had been in complete remission for longer than 20 years.

Entities:  

Mesh:

Year:  1985        PMID: 3967174     DOI: 10.1002/1097-0142(19850215)55:4<794::aid-cncr2820550418>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  87 in total

Review 1.  Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 2.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

3.  Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy?

Authors:  Cho Rok Lee; Haiyoung Son; Sohee Lee; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

4.  Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor.

Authors:  Jürgen Witte; Steffen Lehmann; Michael Wulfert; Quin Yang; Hans D Röher
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

Review 5.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

6.  Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review).

Authors:  Sante Basso Ricci; Ugo Cerchiari
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

7.  Postoperative outcome of insufficient surgery for small differentiated thyroid carcinoma.

Authors:  K Shingu; A Sugenoya; S Kobayashi; Y Kasuga; M Fujimori; K Asanuma; Y Hama; K Ito; M Maruyama; N Itoh; J Amano
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

Review 8.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

9.  BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Authors:  Fei Wang; Shihua Zhao; Xiaopei Shen; Guangwu Zhu; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Mingzhao Xing
Journal:  J Clin Oncol       Date:  2018-08-02       Impact factor: 44.544

Review 10.  Thyroid cancer: a review of treatment and follow-up.

Authors:  L Vini; C Harmer; V R McCready
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.